Dasatinib News and Research

RSS

Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Researchers discover way to reverse brain aging caused by COVID-19

University of Queensland researchers have found a way to reverse a cellular process triggered by COVID-19 that contributes to premature aging of the brain.

22 Nov 2023

Senolytics show promise in combating brain aging and COVID-19 neuropathology

Study reveals that senolytics can reduce aging in human brain organoids and mitigate COVID-19 neuropathology, suggesting their potential as a therapeutic strategy against brain aging and coronavirus-related neurological complications.

15 Nov 2023

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer's disease (AD) patients.

8 Sep 2023

Phase I trial of senolytic therapy shows promise in Alzheimer's disease

Alzheimer's disease is the most common cause of dementia that affects more than 6.5 million Americans, according to the Alzheimer's Association.

8 Sep 2023

New research pinpoints key culprit behind brain cancer metastasis in children

New research pinpoints a key cause of metastasis from an aggressive form of brain cancer in children and provides a potential new therapy for treating these tumors in the future.

6 Mar 2023

Senolytics could be a beneficial therapeutic for COVID neuropathology

Researchers assess the effectiveness of multiple senolytic interventions in removing senescent cells in aged human brain organoids.

22 Jan 2023

Study describes the variations in drug response across genetic subtypes of childhood leukemia

Scientists at St. Jude Children's Research Hospital are reporting the most comprehensive study to date describing the variations in drug response across different genetic subtypes of acute lymphoblastic leukemia (ALL).

5 Jan 2023

Discovery of cellular uptake pathway for larger molecules can be harnessed to create new drugs

A fundamental challenge in drug development is the balance between optimizing a drug's lock-and-key fit with its target and the drug's ability to make its way across the cellular membrane and access that target.

8 Dec 2022

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.

20 Jun 2022

Drug combination without chemotherapy can be effective in treating older patients with Ph+ ALL

The combination of dasatinib, blinatumomab, and prednisone can be effective in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who are not good candidates for intensive chemotherapy treatment.

13 Dec 2021

Potential association between senescence and aging in COVID-19

A review published in Cells discussed characteristics of cellular senescence and its potential role in COVID-19.

9 Dec 2021

Clearing old, dysfunctional cells in fat alleviates diabetes

Eliminating old, dysfunctional cells in human fat also alleviates signs of diabetes, researchers from UConn Health report. The discovery could lead to new treatments for Type 2 diabetes and other metabolic diseases.

22 Nov 2021

Cancer drugs could be repurposed as potential therapies for Alzheimer's disease

Existing and emerging cancer drugs could be repurposed as therapies to be tested in clinical trials for people at genetic risk of Alzheimer's disease, according to a new study published in Science Advances.

10 Nov 2021

Celastrol shows potential anti-SARS-CoV-2 activity

A new study published on the bioRxiv* preprint server focuses on the in-silico predictions to repurpose existing drug compounds, that may have the ability to reverse the SARS-CoV-2 gene expression induced in host cells.

23 Apr 2021

Study sheds light on potential new treatment approach in AML patients

Tyrosine kinases are protein enzymes that have many functions within cells, including cell signaling, growth, and division. Sometimes these enzymes can be overactive, which helps cancer cells survive and multiply.

31 Jul 2020

YAP signal pathway plays a vital role in the onset of head-and-neck cancer

Joint research between Kobe University and National Hospital Organization Kyushu Cancer Center has revealed that mice with mutations in the YAP signal pathway develop head-and-neck cancer over an extremely short period of time (world's fastest cancer onset mouse model), indicating that this pathway plays a crucial role in the onset of these cancers.

25 Mar 2020

First randomized clinical trial compares targeted therapies for acute lymphoblastic leukemia

Researchers from St. Jude Children's Research Hospital and the Chinese Children's Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome.

17 Jan 2020

Researchers discover new chemical weapon to fight against cancer

The fight against cancer involves eradicating cancer cells but current treatments inevitably have negative consequences on healthy cells.

23 Oct 2019

Physicians more likely to prescribe drugs of manufacturers who paid them money

In a study published in The Oncologist, physicians treating certain cancers who consistently received payments from a cancer drug's manufacturer were more likely to prescribe that drug over alternative treatments.

6 Feb 2019